CMND · Clearmind Medicine Inc.

This 6-K filing conveys no financial results, executive changes, or material agreements, but signals meaningful regulatory and legislative progress for Clearmind’s core asset, CMND-100 (MEAI). The Executive Order represents a high-level policy shift that directly benefits companies developing FDA-designated breakthrough psychedelic therapies — particularly non-hallucinogenic neuroplastogens like MEAI, which Clearmind emphasizes as safer and more scalable. Its explicit naming in H.R. 7091 — a bipartisan bill focused on expanding veterans’ access to emerging treatments — is a rare and concrete validation of the compound’s strategic relevance to public health priorities, especially for alcohol use disorder and treatment-resistant PTSD. While the bill remains proposed and subject to enactment, its inclusion elevates MEAI’s visibility among policymakers and may facilitate future VA engagement, trial funding, or real-world evidence generation. Coupled with ongoing Phase I/IIa trials at Yale and Johns Hopkins, this positions Clearmind at an inflection point where scientific development intersects with accelerating regulatory tailwinds — though no clinical data, timelines, or commercial commitments are disclosed. Investors should monitor legislative progress on H.R. 7091 and upcoming clinical readouts as near-term catalysts.